Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Hutchison China MediTech Limited

http://www.hmplglobal.com

Latest From Hutchison China MediTech Limited

Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug

Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.

Deals Business Strategies

Chi-Med Extends Oncology Commercial Reach To Realize China Potential

Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.

China Business Strategies

Finance Watch: 14 Biopharma IPOs In One Remarkable Month

Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.

Financing Business Strategies

Zai Lab On Portfolio Strategy In Post Coronavirus China

Portfolio management is high on innovative drug maker’s mind amid aftermath of coronavirus outbreak.

China Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Chi-Med
    • Hutchison Whampoa Sinopharm Pharmaceuticals Company Limited
    • Hutchison MediPharma Limited
UsernamePublicRestriction

Register